Treatment of coronary artery in-stent restenosis

Expert Review of Cardiovascular Therapy

Volumn 15, Issue 3, 2017, Pages 191-202

  Kokkinidis, Damianos G ^a   Waldo, Stephen W ^a   Armstrong, Ehrin J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary artery disease; drug coated balloons; drug eluting stents; in stent restenosis; percutaneous coronary intervention

Indexed keywords

ADJUVANT THERAPY; ATHERECTOMY; BIORESORBABLE VASCULAR STENT; BRACHYTHERAPY; CORONARY ARTERY IN STENT RESTENOSIS; CORONARY ATHERECTOMY; CUTTING BALLOON ANGIOPLASTY; DRUG COATED BALLOON THERAPY; DRUG ELUTING STENT; EXCIMER LASER; EXCIMER LASER ATHERECTOMY; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROTATIONAL ATHERECTOMY; SCORING BALLOON ANGIOPLASTY; VASCULAR BRACHYTHERAPY; ADVERSE EFFECTS; CORONARY BLOOD VESSEL; CORONARY RESTENOSIS; PATHOLOGY; PROSTHESIS DESIGN; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; HUMANS; PROSTHESIS DESIGN; STENTS; TREATMENT OUTCOME;

EID: 85014582034     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1080/14779072.2017.1284588     Document Type: Review

References (115)

1. Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014;100(2):153–159.
2. Farooq V, Gogas BD, Serruys PW., Restenosis:delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv. 2011;4(2):195–205.
3. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315–1323.
4. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773–1780.
5. Alfonso F, Byrne RA, Rivero F, et al. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63(24):2659–2673.
6. Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897–1907.
7. Alfonso F, Perez-Vizcayno MJ, Dutary J, et al. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent:balloon Angioplasty versus drug-eluting stent]). JACC Cardiovasc Interv. 2012;5(7):728–737.•• Major randomized trial of switch strategy.
8. Nojima Y, Yasuoka Y, Kume K, et al. Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis. Coron Artery Dis. 2014;25(8):638–644.
9. Vyas A, Schweizer M, Malhotra A, et al. Meta-analysis of same versus different stent for drug-eluting stent restenosis. Am J Cardiol. 2014;113(4):601–606.
10. Windecker S, Kolh P, Alfonso F, et al. ESC/EACTS Guidelines on myocardial revascularization:the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–2619.
11. Levine GN, Bates ER, Blankenship JC, et al. ACCF/AHA/SCAI Guideline for percutaneous coronary intervention. A report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol. 2011;58(24):e44–122.
12. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis:classification and implications for long-term outcome. Circulation. 1999;100(18):1872–1878.
13. Solinas E, Dangas G, Kirtane AJ, et al. Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. Am J Cardiol. 2008;102(3):311–315.
14. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents:a collaborative network meta-analysis. Lancet (London, England). 2007;370(9591):937–948.
15. Hofma SH, Smits PC, Brouwer J, et al. Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction:three-year results of the XAMI trial. EuroIntervention. 2015;10(11):1280–1283.
16. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE):a randomised trial. Lancet (London, England). 2010;375(9710):201–209.
17. Koster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet (London, England). 2000;356(9245):1895–1897.
18. Sonoda S, Morino Y, Ako J, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation:serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol. 2004;43(11):1959–1963.
19. Chung IM, Gold HK, Schwartz SM, et al. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol. 2002;40(12):2072–2081.
20. Park SJ, Kang SJ, Virmani R, et al. In-stent neoatherosclerosis:a final common pathway of late stent failure. J Am Coll Cardiol. 2012;59(23):2051–2057.• Excellent overview of neoatherosclerosis.
21. Hecht HS, Polena S, Jelnin V, et al. Stent gap by 64-detector computed tomographic angiography relationship to in-stent restenosis, fracture, and overlap failure. J Am Coll Cardiol. 2009;54(21):1949–1959.
22. Aoki J, Nakazawa G, Tanabe K, et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv. 2007;69(3):380–386.
23. Kandzari DE, Rao SV, Moses JW, et al. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions:the ACROSS/TOSCA-4 (Approaches to chronic occlusions with sirolimus-eluting stents/total occlusion study of coronary arteries-4) trial. JACC Cardiovasc Interv. 2009;2(2):97–106.
24. Umeda H, Gochi T, Iwase M, et al. Frequency, predictors and outcome of stent fracture after sirolimus-eluting stent implantation. Int J Cardiol. 2009;133(3):321–326.
25. McDermott MM, Greenland P, Liu K, et al. Vulnerable blood in high risk vascular patients:study design and methods. Contemp Clin Trials. 2014;38(1):121–129.
26. Fujii K, Mintz GS, Kobayashi Y, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation. 2004;109(9):1085–1088.
27. Steinberg DH, Mintz GS, Mandinov L, et al. Long-term impact of routinely detected early and late incomplete stent apposition:an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies. JACC Cardiovasc Interv. 2010;3(5):486–494.
28. Hwang CW, Levin AD, Jonas M, et al. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation. 2005;111(13):1619–1626.
29. Balakrishnan B, Tzafriri AR, Seifert P, et al. Strut position, blood flow, and drug deposition:implications for single and overlapping drug-eluting stents. Circulation. 2005;111(22):2958–2965.
30. Jakabcin J, Spacek R, Bystron M, et al. Long-term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS. Catheter Cardiovasc Interv. 2010;75(4):578–583.
31. Parise H, Maehara A, Stone GW, et al. Meta-analysis of randomized studies comparing intravascular ultrasound versus angiographic guidance of percutaneous coronary intervention in pre-drug-eluting stent era. Am J Cardiol. 2011;107(3):374–382.
32. Habara M, Nasu K, Terashima M, et al. Impact of frequency-domain optical coherence tomography guidance for optimal coronary stent implantation in comparison with intravascular ultrasound guidance. Circ Cardiovasc Interv. 2012;5(2):193–201.
33. Ohlmann P, Mintz GS, Kim SW, et al. Intravascular ultrasound findings in patients with restenosis of sirolimus- and paclitaxel-eluting stents. Int J Cardiol. 2008;125(1):11–15.
34. Chieffo A, Latib A, Caussin C, et al. A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions:the AVIO trial. Am Heart J. 2013;165(1):65–72.
35. Kang SJ, Mintz GS, Akasaka T, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation. Circulation. 2011;123(25):2954–2963.
36. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis:strut coverage as a marker of endothelialization. Circulation. 2007;115(18):2435–2441.
37. Prati F, Di Vito L, Biondi-Zoccai G, et al. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention:the Centro per la Lotta contro l’Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. EuroIntervention. 2012;8(7):823–829.
38. Gonzalo N, Serruys PW, Okamura T, et al. Optical coherence tomography patterns of stent restenosis. Am Heart J. 2009;158(2):284–293.
39. Iannaccone M, D’Ascenzo F, Templin C, et al. Optical coherence tomography evaluation of intermediate-term healing of different stent types:systemic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2016;jew070. [Epub ahead of print].
40. Sakamoto T, Kawarabayashi T, Taguchi H, et al. Intravascular ultrasound-guided balloon angioplasty for treatment of in-stent restenosis. Catheter Cardiovasc Interv. 1999;47(3):298–303.
41. Albiero R, Silber S, Di Mario C, et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis:results of the restenosis cutting balloon evaluation trial (RESCUT). J Am Coll Cardiol. 2004;43(6):943–949.
42. Alfonso F, Perez-Vizcayno MJ, Gomez-Recio M, et al. Implications of the “watermelon seeding” phenomenon during coronary interventions for in-stent restenosis. Catheter Cardiovasc Interv. 2005;66(4):521–527.
43. Rittger H, Waliszewski M, Brachmann J, et al. Long-term outcomes after treatment with a paclitaxel-coated balloon versus balloon angioplasty:insights from the PEPCAD-DES study (Treatment of Drug-eluting Stent [DES] in-stent restenosis with sequent please paclitaxel-coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter). JACC Cardiovasc Interv. 2015;8(13):1695–1700.•• Trial of drug coated balloon angioplasty for treatment of ISR.
44. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355(20):2113–2124.
45. Scheller B, Clever YP, Kelsch B, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv. 2012;5(3):323–330.
46. Barath P, Fishbein MC, Vari S, et al. Cutting balloon:a novel approach to percutaneous angioplasty. Am J Cardiol. 1991;68(11):1249–1252.
47. Tsetis D, Morgan R, Belli AM. Cutting balloons for the treatment of vascular stenoses. Eur Radiol. 2006;16(8):1675–1683.
48. Song HG, Park DW, Kim YH, et al. Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation. J Am Coll Cardiol. 2012;59(12):1093–1100.
49. Scheller B, Fontaine T, Mangner N, et al. A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis:results from the multi-center randomized controlled PATENT-C first in human trial. Catheter Cardiovasc Interv. 2016;88(1):51–59.•• Trial of a novel drug coated scoring balloon.
50. Sims EC, Rothman MT, Warner TD, et al. Coronary artery brachytherapy. Clin Oncol (R Coll Radiol). 2002;14(4):313–326.
51. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;344(4):250–256.
52. Waksman R, Raizner AE, Yeung AC, et al. Use of localised intracoronary beta radiation in treatment of in-stent restenosis:the INHIBIT randomised controlled trial. Lancet (London, England). 2002;359(9306):551–557.
53. Popma JJ, Suntharalingam M, Lansky AJ, et al. Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation. 2002;106(9):1090–1096.
54. Costa MA, Sabate M, van der Giessen WJ, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation. 1999;100(8):789–792.
55. Waksman R, Bhargava B, Mintz GS, et al. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol. 2000;36(1):65–68.
56. Waksman R, Ajani AE, White RL, et al. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Circulation. 2004;109(3):340–344.
57. Baierl V, Baumgartner S, Pollinger B, et al. Three-year clinical follow-up after strontium-90/yttrium-90 beta-irradiation for the treatment of in-stent coronary restenosis. Am J Cardiol. 2005;96(10):1399–1403.
58. Stone GW, Ellis SG, O’Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents:the TAXUS V ISR randomized trial. Jama. 2006;295(11):1253–1263.
59. Holmes DR, Jr., Teirstein P, Satler L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents:the SISR randomized trial. Jama. 2006;295(11):1264–1273.
60. Negi SI, Torguson R, Gai J, et al. Intracoronary brachytherapy for recurrent drug-eluting stent failure. JACC Cardiovasc Interv. 2016;9(12):1259–1265.• Brachytherapy for recurrent restenosis.
61. Tomey MI, Kini AS, Sharma SK. Current status of rotational atherectomy. JACC Cardiovasc Interv. 2014;7(4):345–353.
62. Sharma SK, Kini A, Mehran R, et al. Randomized trial of rotational atherectomy versus balloon angioplasty for diffuse in-stent restenosis (ROSTER). Am Heart J. 2004;147(1):16–22.
63. Vom Dahl J, Dietz U, Haager PK, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis:results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). Circulation. 2002;105(5):583–588.
64. Lee SW, Park SW, Hong MK, et al. Comparison of angiographic and clinical outcomes between rotational atherectomy and cutting balloon angioplasty followed by radiation therapy with a rhenium 188-mercaptoacetyltriglycine-filled balloon in the treatment of diffuse in-stent restenosis. Am Heart J. 2005;150(3):577–582.
65. Mehran R, Mintz GS, Satler LF, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty:mechanisms and results compared with PTCA alone. Circulation. 1997;96(7):2183–2189.
66. Mehran R, Dangas G, Mintz GS, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy:comparative mechanisms and results. Circulation. 2000;101(21):2484–2489.
67. Latib A, Takagi K, Chizzola G, et al. Excimer Laser LEsion modification to expand non-dilatable stents:the ELLEMENT registry. Cardiovasc Revasc Med. 2014;15(1):8–12.• Excime laser for treatment of underexpanded coroary stents.
68. Alfonso F, Scheller B. Management of recurrent in-stent restenosis:onion skin full metal jacket? EuroIntervention. 2013;9(7):781–785.
69. Kastrati A, Mehilli J, Von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis:a randomized controlled trial. Jama. 2005;293(2):165–171.
70. Alfonso F, Perez-Vizcayno MJ, Hernandez R, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis:results of the restenosis intrastent:balloon angioplasty versus elective sirolimus-eluting stenting (RIBS-II) trial. J Am Coll Cardiol. 2006;47(11):2152–2160.
71. Mehilli J, Byrne RA, Tiroch K, et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents:the ISAR-DESIRE 2 (intracoronary stenting and angiographic results:drug eluting stents for in-stent restenosis 2) study. J Am Coll Cardiol. 2010;55(24):2710–2716.
72. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353(7):653–662.
73. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353(7):663–670.
74. Schomig A, Dibra A, Windecker S, et al. A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents versus Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease. J Am Coll Cardiol. 2007;50(14):1373–1380.
75. Sarno G, Lagerqvist B, Frobert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents:a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012;33(5):606–613.
76. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663–1674.
77. Alfonso F, Perez-Vizcayno MJ. Garcia Del Blanco B, et al. Long-Term Results of Everolimus-Eluting Stents versus Drug-Eluting Balloons in Patients with Bare-Metal In-Stent Restenosis:3-Year Follow-Up of the RIBS V Clinical Trial. JACC Cardiovasc Interv. 2016;9(12):1246–1255.•• Drug eluting stents vs. drug eluting balloons for treatment of ISR.
78. Alfonso F, Perez-Vizcayno MJ, Cardenas A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis:the RIBS V clinical trial (Restenosis intra-stent of bare metal stents:paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014;63(14):1378–1386.
79. Alfonso F, Perez-Vizcayno MJ, Cardenas A, et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting Stents:the RIBS IV Randomized clinical trial. J Am Coll Cardiol. 2015;66(1):23–33.
80. Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis:a network meta-analysis. Lancet (London, England). 2015;386(9994):655–664.
81. Richardt G, Leschke M, Abdel-Wahab M, et al. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis:2-year results from a pooled analysis. JACC Cardiovasc Interv. 2013;6(9):905–913.
82. Steinberg DH, Gaglia MA, Jr., Pinto Slottow TL, et al. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. Am J Cardiol. 2009;103(4):491–495.
83. Rittger H, Brachmann J, Sinha AM, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis:the PEPCAD-DES study. J Am Coll Cardiol. 2012;59(15):1377–1382.
84. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis:the three-year results of the PEPCAD II ISR study. EuroIntervention. 2015;11(8):926–934.
85. Pleva L, Kukla P, Kusnierova P, et al. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus-eluting stents in the treatment of coronary in-stent restenosis:the treatment of in-stent restenosis study. Circ Cardiovasc Interv. 2016;9(4):e003316.
86. Hong SJ, Ahn CM, Kim B-K, et al. Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents:intravascular ultrasound volumetric analysis (RESTENT-ISR trial). Eur Heart J. 2016;37:3409–3418.
87. Adriaenssens T, Dens J, Ughi G, et al. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis:the SEDUCE (Safety and efficacy of a drug elUting balloon in coronary artery rEstenosis) randomised clinical trial. EuroIntervention. 2014;10(4):439–448.
88. Campo G, Punzetti S, Malagu M, et al. Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY Trial Substudy. I J Cardiol. 2014;173(2):343–345.
89. Jamshidi P, Nyffenegger T, Sabti Z, et al. A novel approach to treat in-stent restenosis:6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold. EuroIntervention. 2016;11(13):1479–1486.
90. Gomez-Lara J, Brugaletta S, Diletti R, et al. Agreement and reproducibility of gray-scale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. Catheter Cardiovasc Interv. 2012;79(6):890–902.
91. Moscarella E, Varricchio A, Stabile E, et al. Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis:results from a multicenter Italian experience. Int J Cardiol. 2015;199:366–372.
92. Ielasi A, Latib A, Naganuma T, et al. Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis. Int J Cardiol. 2014;173(3):513–514.
93. Rivero F, Bastante T, Cuesta J, et al. Treatment of in-stent restenosis with bioresorbable vascular scaffolds:optical coherence tomography insights. Can J Cardiol. 2015;31(3):255–259.
94. Dorr O, Liebetrau C, Wiebe J, et al. Bioresorbable scaffolds for the treatment of in-stent restenosis. Heart Vessels. 2015;30(2):265–269.
95. Karabulut A, Demirci Y. Cutting balloon use may ease the optimal apposition of bioresorbable vascular scaffold in in-stent stenosis. Postepy Kardiol Interwencyjnej. 2015;11(1):64–66.
96. Wong KL, Fan KY, Jim MH. Successful use of bioresorbable vascular scaffold in in-stent restenosis previously exposed to vascular brachytherapy. Int J Cardiol. 2015;181:1–2.
97. Bastante T, Rivero F, Benedicto A, et al. Recurrent neoatherosclerosis after bioresorbable vascular scaffold treatment of in-stent restenosis. JACC Cardiovasc Interv. 2015;8(9):1264–1265.
98. Rivero F, Benedicto A, Bastante T, et al. Subacute thrombosis of a bioresorbable vascular scaffold implanted for recurrent in-stent restenosis. EuroIntervention. 2015;11(7):780.
99. Byrne RA, Joner M, Alfonso F, et al. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Reviews Cardiol. 2014;11(1):13–23.
100. Alfonso F, Jimenez-Quevedo P, Gonzalo N, et al. Neoatherosclerosis after paclitaxel-coated balloon angioplasty for in-stent restenosis. Circulation. 2014;129(8):923–925.
101. Yumoto K, Watanabe T, Fukuzawa T, et al. Development of late stent malapposition after paclitaxel-coated balloon angioplasty for in-stent neoatherosclerosis. JACC Cardiovasc Interv. 2015;8(10):e167–9.
102. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents:the efficacy of xience/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125(3):505–513.
103. Clever YP, Peters D, Calisse J, et al. Novel sirolimus–coated balloon catheter:in vivo evaluation in a porcine coronary model. Circ Cardiovasc Interv. 2016;9:4.
104. Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3):a randomised, open-label trial. Lancet (London, England). 2013;381(9865):461–467.
105. Kufner S, Cassese S, Valeskini M, et al. Long-term efficacy and safety of paclitaxel-eluting balloon for the treatment of drug-eluting stent restenosis:3-year results of a randomized controlled trial. JACC Cardiovasc Interv. 2015;8(7):877–884.
106. Habara S, Mitsudo K, Kadota K, et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv. 2011;4(2):149–154.
107. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119(23):2986–2994.
108. Habara S, Kadota K, Kanazawa T, et al. Paclitaxel-coated balloon catheter compared with drug-eluting stent for drug-eluting stent restenosis in routine clinical practice. EuroIntervention. 2016;11(10):1098–1105.
109. Giacoppo D, Gargiulo G, Aruta P, et al. Treatment strategies for coronary in-stent restenosis:systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. BMJ (Clinical Research Ed). 2015;351:h5392.
110. Lee JM, Park J, Kang J, et al. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis:a network meta-analysis of 11 randomized, controlled trials. JACC Cardiovasc Interv. 2015;8(3):382–394.•• Meta-analysis of treatment strategies for ISR.
111. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice:data from a large two-institutional cohort study. Lancet (London, England). 2007;369(9562):667–678.
112. Cassese S, Byrne RA, Tada T, et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era:a meta-analysis of randomized trials. Eur Heart J. 2012;33(24):3078–3087.
113. Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy:the RESET trial (Real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340–1348.
114. Kamishirado H, Inoue T, Sakuma M, et al. Effects of statins on restenosis after coronary stent implantation. Angiology. 2007;58(1):55–60.
115. Jaschke B, Michaelis C, Milz S, et al. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res. 2005;68(3):483–492.